Menu
Back to Journals » Risk Management and Healthcare Policy » Volume 16
Original Research
Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 1,859 | Dovepress* | 1,784+ | 54 | 1,838 | |
| PubMed Central* | 75 | 33 | 108 | ||
| Totals | 1,859 | 87 | 1,946 | ||
| *Since 22 November 2023 | |||||
View citations on PubMed Central and Google Scholar